Today’s article highlights two clinical-stage biotech stocks that analysts believe are not only likely to be winners this year, but that have the potential to double – or more – in value. The first of these companies is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases, while the second is focused on the discovery and development of precision medicines for cancer. For more, CLICK HERE.
These 2 Biotech Stocks Could Double – Or More – This Year
- by RobH
Tags:2021 Biotech InvestmentsBiotech StocksClinical-Stage Biotech StocksDoubling BiotechsDoubling StocksInvestorMarket AnalystsStock MarketstocksValue